Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
T

Trastuzumab Emtansine

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

Yes

Post-marketing information

Dear Healthcare Professional Letters

Subsidy Information and Financing Scheme

Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List

Active ingredient: Trastuzumab Emtansine

General information

Subsidy Information and Financing Scheme

[MSHL] Trastuzumab Emtansine Powder For Concentrate For Solution For Infusion 100 mg, 160 mg

  1. Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles.

  2. Treatment of HER2-positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and chemotherapy.

View legend

Drug Guidance for Subsidy

01/09/2023 Review of cancer drugs for treating early or advanced HER2-positive breast cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing pertuzumab, pertuzumab plus trastuzumab fixed-dose subcutaneous (SC) injection, trastuzumab emtansine or tucatinib on the Medication Assistance Fund (MAF) for treating human epidermal growth factor receptor (HER2)-positive breast cancer due to unfavourable cost-effectiveness at the prices proposed by the manufacturer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

View legend

Post Marketing Information

DHCPL 24/01/2014 Potential risk for medication error between Kadcyla® (trastuzumab emtansine) and Herceptin® (trastuzumab) resulting from name confusion

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Kadcyla Powder For Concentrate For Solution For Infusion 100 mg

  1. KK Women's and Children's Hospital

  2. Khoo Teck Puat Hospital

  3. National Cancer Centre

  4. Ng Teng Fong General Hospital

  5. National University Hospital

  6. Tan Tock Seng Hospital

Kadcyla Powder For Concentrate For Solution For Infusion 160 mg

  1. KK Women's and Children's Hospital

  2. Khoo Teck Puat Hospital

  3. National Cancer Centre

  4. Tan Tock Seng Hospital

List of monographs containing this active ingredient

Trastuzumab Emtansine [Kadcyla]

Back to top